Indian Journal of Pharmacy Practice logo
Submit
Indian Journal of Pharmacy PracticeACADEMIC PUBLISHING
Review

A systematic review of risks and benefits of sitagliptin and saxagliptin monotherapies and metformin combination therapies

1

  1. 1University of New Mexico, College of Pharmacy, Department of Pharmacy Practice, 402 Cornell Dr. SE, Apt # 2, Albuquerque, NM, 87106, USA.

CORRESPONDENCE

Vishvas G

University of New Mexico College of Pharmacy, Department of Pharmacy Practice, 402 Cornell Dr. SE, Apt # 2, Albuquerque, NM, 87106, USA.

Vishvas4588@gmail.com

Received: 25-04-2010; Accepted: 12-05-2011.

Volume 4, Issue 2 · pp. 10-15 · 2011 · DOI:

ABSTRACT

India has the highest prevalence of diabetes (50.8 million people). Sitagliptin and saxagliptin are the two newer drugs approved for the treatment of type 2 diabetes mellitus. The purpose of this paper is to conduct a systematic literature review of the pharmacological and pharmacoeconomical profiles of sitagliptin and saxaglitpin. Using the MeSH terms in PubMed, a total of four searches were conducted: only sitagliptin, only saxagliptin, and sitagliptin and saxagliptin combined with economics, separately.Various articles were found and analyzed: only sitagliptin (n=125), only saxagliptin (n=34), sitagliptin+economics (n=11), and saxagliptin+economics (n=3). These searches were then narrowed down using the inclusion and exclusion criteria: only sitagliptin (n=26), only saxagliptin (n=9), sitagliptin+economics (n=0), and saxagliptin+economics (n=0). The pooled results of clinical trials show that sitagliptin and saxaglitpin have a good general safety profile. However, no formal economic evaluation of sitagliptin and saxaglitpin in India were found during the search. Formal economic evaluations of sitagliptin and saxaglitpin costs and consequences are required.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    G, V. (2011). A systematic review of risks and benefits of sitagliptin and saxagliptin monotherapies and metformin combination therapies. Indian Journal of Pharmacy Practice, 4(2), 10-15.

    Copyright and licence

    © 2011 Author(s)

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. CC BY 4.0